KLK3 and posterior cortical atrophy: Several blood or serum-based biomarkers used for diagnosis of PCa, such as the US FDA approved tests (PSA, fPSA, Prostate Health Index) [7–10], or clinical laboratory improvement amendments (CLIA)-approved biomarkers (4Kscore) [11–14], and also test pending approval, such as STHLM3 and STHLM3MRI [15–19] have been developed in recent years.